[go: up one dir, main page]

BR9900523A - Pharmaceutical composition of spiny proteins and their use - Google Patents

Pharmaceutical composition of spiny proteins and their use

Info

Publication number
BR9900523A
BR9900523A BR9900523-9A BR9900523A BR9900523A BR 9900523 A BR9900523 A BR 9900523A BR 9900523 A BR9900523 A BR 9900523A BR 9900523 A BR9900523 A BR 9900523A
Authority
BR
Brazil
Prior art keywords
spiny
vehicle
protein
proteins
pharmaceutical composition
Prior art date
Application number
BR9900523-9A
Other languages
Portuguese (pt)
Inventor
Kurt Lang
Apollon Papadimitriou
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of BR9900523A publication Critical patent/BR9900523A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biological Depolymerization Polymers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO FARMACêUTICA DE PROTEìNAS ESPINHOSAS E USO DAS MESMAS"<D>. Composição farmacêutica de uma proteína espinhosa, que é caracterizada pelo fato de a proteína espinhosa estar ligada a um veículo hidrofílico que é biocompatível e biodegradável, em que o veículo é um polímero que - se liga à proteína espinhosa como um veículo negativamente carregado, como resultado de interações iónicas, - não desnatura a proteína espinhosa quando ela se liga ao veículo, - contém pelo menos de 0,1 a 2 resíduos negativamente carregados por monómero sob condições neutras, - contém a carga na forma de grupos ácidos, - tem um peso molecular médio de pelo menos 50.000 Da, - e não contém agarose, que libera de maneira reversível e ativa proteínas espinhosas 'in vivo' de um veículo, de maneira retardada.Invention Patent: <B> "PHARMACEUTICAL COMPOSITION OF SPINY PROTEINS AND USE OF THE SAME" <D>. Pharmaceutical composition of a spiny protein, which is characterized by the fact that the spiny protein is linked to a hydrophilic vehicle that is biocompatible and biodegradable, in which the vehicle is a polymer that - binds to the spiny protein as a negatively charged vehicle, as a result of ionic interactions, - does not denature the spiny protein when it binds to the vehicle, - contains at least 0.1 to 2 negatively charged residues per monomer under neutral conditions, - contains the charge in the form of acidic groups, - has a weight average molecular weight of at least 50,000 Da, - and does not contain agarose, which reversibly releases and activates thorny proteins 'in vivo' from a vehicle, in a delayed manner.

BR9900523-9A 1998-02-04 1999-02-03 Pharmaceutical composition of spiny proteins and their use BR9900523A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98101893 1998-02-04

Publications (1)

Publication Number Publication Date
BR9900523A true BR9900523A (en) 2000-05-02

Family

ID=8231349

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9900523-9A BR9900523A (en) 1998-02-04 1999-02-03 Pharmaceutical composition of spiny proteins and their use

Country Status (8)

Country Link
AR (1) AR014530A1 (en)
BR (1) BR9900523A (en)
HR (1) HRP990036A2 (en)
ID (1) ID22356A (en)
PE (1) PE20000241A1 (en)
PL (1) PL331201A1 (en)
TR (1) TR199900197A2 (en)
ZA (1) ZA99887B (en)

Also Published As

Publication number Publication date
PL331201A1 (en) 1999-08-16
ZA99887B (en) 1999-08-04
HRP990036A2 (en) 1999-08-31
AR014530A1 (en) 2001-02-28
TR199900197A2 (en) 1999-08-23
PE20000241A1 (en) 2000-04-08
ID22356A (en) 1999-10-07

Similar Documents

Publication Publication Date Title
TR200003281T2 (en) Antibodies to CD-23, their derivatives and therapeutic uses.
BR9714434A (en) Stable liquid interferon formulations
BR0100046A (en) Water-soluble or water-swellable cross-linked copolymers
BR9808965A (en) Edible compositions including particulate gel
WO1999010022A3 (en) Methods and compositions to prevent formation of adhesions in biological tissues
BR9812018A (en) Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
DK0808367T3 (en) Vascular mucosal dressings and their use
WO2006056464A3 (en) Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
ATE454124T1 (en) RECOMBINANT ANTI-CD30 ANTIBODIES AND USES THEREOF
BR9710243A (en) Processes and compositions for reducing or eliminating the formation of post-surgical adhesion.
BR122016022033B8 (en) isolated polypeptide conjugates showing factor viii procoagulant activity, their use and pharmaceutical composition
EP3569610A3 (en) Molecules with extended half lives, compositions and uses thereof
BR9815159A (en) Preparation of site-specific polyethylene glycol-grf conjugates
BR9710350A (en) Stnfr truncated tumor necrosis-binding protein and polyvalent polynucleotide nucleic acid sequence polynucleotide vector c-cell procardiotic host pharmaceutical composition processes for silvering a disease mediated by tnf e to prepare a pharmaceutical composition using the tumor necrosis factor binding protein and kit
PT100850A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A SYNERGY MIX OF A URICOSURIC AGENT, IN PARTICULAR, OF PROBENECID, WITH AN ANTAGONIST AGENT OF AMINOACIDES EXCITING, ESPECIALLY, A DERIVATIVE OF SUBSTITUTED CHINOXALINE AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
BRPI0518762A2 (en) drug fusion, drug conjugate, recombinant or isolated nucleic acid, nucleic acid construct, host cell, method for producing drug fusion, pharmaceutical composition, method for treating an individual having an inflammatory disease, use of a drug conjugate or drug fusion, and, drug composition
BR0013638A (en) New interferon beta-like molecules
BR9607628A (en) Biologically isolated proteinaceous molecule, recombinant molecule, peptide fragment, nucleic acid molecule, pharmaceutical composition, and processes for preparing a recombinant molecule and for inducing astroglial proliferation in a mammal
BRPI0621656B8 (en) binary mixtures of hyaluronic acid and their therapeutic use
BR9900523A (en) Pharmaceutical composition of spiny proteins and their use
CA2435466A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of heart disease
AU2002366303B2 (en) Enzymatic cleavable reagents for specific delivery to disease sites
DE69932113D1 (en) Pharmaceutical compositions of hedgehog proteins and their use
BR9910175A (en) Composition of polyol with charge and polyurethane with charge
PT99608A (en) A process for the preparation of a two phase composition for topical application comprising a phase with a solubilized drug such as a steroid and a phase with an aqueous vehicle.

Legal Events

Date Code Title Description
TC Change of proprietor's name
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 3A, 4A, 5A, 6A, 7A E 8A ANUDIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.

B15K Others concerning applications: alteration of classification

Ipc: A61K 9/22 (2006.01), A61K 31/728 (2006.0